Genentech... Another Win!

It sounds like I'm repeating myself once again, but Genentech has another winner. This time it's Lucentis, a drug for wet aged-related macular degeneration. The drug actually improved vision in their phase 3 trials, which was a positive surprise. Most people were just expecting the drug to preserve vision. This is very bad for Eye Tech (EYET), check out the stock in after hours (down 27%)... ugggly! I keep kicking myself for not picking up more Genentech in the 50s. Oh well... no point in looking back.